Acumen initiated with bullish view at Deutsche Bank, here’s why

Deutsche Bank analyst Neena Bitritto-Garg initiated coverage of Acumen with a Buy rating and $8 price target. Acumen is developing ACU193 for Alzheimer’s disease and Phase 1 data for ACU193 “actually demonstrated modest plaque lowering on amyloid PET, a result we did not expect given selectivity for oligomers,” the analyst tells investors. The firm sees the potential for meaningful upside on success in late-stage Alzheimer’s studies and scarcity value, the analyst tells investors.